Maxim initiated coverage of Avenue Therapeutics with a Buy rating and 75c price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATXI:
- Avenue Therapeutics to present preclinical in vivo data on BAER-101
- Avenue Therapeutics reports Q3 EPS 6c vs (45c) last year
- Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
- Avenue Therapeutics prices 16.6M units at 30.06c in public offering